Log in to search using one of your social media accounts:

 

FDA Approves First Pill with Digital Tracker
The FDA has approved a new version of the antipsychotic aripiprazole embedded with a digital sensor to allow patients to track when the medication was... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 15, 2017 Category: Primary Care Source Type: news

Digital pill could address a "big problem" with medication
CBS News chief medical correspondent Dr. Jon LaPook explains how the digital pill, Abilify MyCite, works (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2017 Category: Consumer Health News Source Type: news

Otsuka, Proteus finally win FDA approval for sensor-equipped Abilify
The first drug in the US with a digital ingestion tracking system has been approved by the FDA. The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults. (Source: mobihealthnews)
Source: mobihealthnews - November 14, 2017 Category: Information Technology Source Type: news

FDA approves first trackable pill that syncs with a phone
The FDA approved a pill that tracks when patients take their prescribed psychiatric drug. The medication, Abilify MyCite, is a variation on a drug used to treat schizophrenia and bipolar disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA Clears Drug With Ingestible Digital Tracker FDA Clears Drug With Ingestible Digital Tracker
Abilify MyCite is the first drug approved in the United States that has a digital tracking system for patients and providers to monitor medication intake.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

'Digital Pill' Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA OKs First 'Digital Pill' That Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA approves first pill with sensor to track ingestion
The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an add-on treatment for depression in adults. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first pill with sensor to track ingestion appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Patient Monitoring Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

' Digital Pill', Abilify Mycite, Tells Doctor When Patient Takes It
TUESDAY, Nov. 14, 2017 -- The first drug designed to alert a doctor when a patient takes the medication has been approved by the U.S. Food and Drug Administration. Abilify MyCite (aripiprazole with sensor) has an embedded sensor that sends a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA OKs First'Digital Pill', Abilify Mycite, That Lets Doctors Know It's Been Taken
TUESDAY, Nov. 14, 2017 -- Offering both the promise of better patient compliance with health care, but also fears of a medical " Big Brother, " a newly approved " digital pill " allows physicians to track whether or not it's been ingested by... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2017 Category: General Medicine Source Type: news

FDA approves first drug in U.S. with digital ingestion tracking
(Reuters) - The U.S. Food and Drug Administration said on Monday that it had approved Otsuka Pharmaceutical Co Ltd's Abilify MyCite, the first drug with a digital ingestion tracking system to be approved in the United States. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 14, 2017 Category: American Health Source Type: news

FDA Approves Pill with Sensor that Digitally Tracks if Patients Have Ingested their Medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: eHealth News EU)
Source: eHealth News EU - November 14, 2017 Category: Information Technology Tags: Featured Development Research and Development Source Type: news

FDA approves pill with sensor that digitally tracks if patients have ingested their medication
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults. (Source: World Pharma News)
Source: World Pharma News - November 14, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 -- The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 13, 2017 Category: Drugs & Pharmacology Source Type: news

Aripiprazole May Reduce Cocaine Cravings in People With Schizophrenia Aripiprazole May Reduce Cocaine Cravings in People With Schizophrenia
In people with schizophrenia, the dopamine modulator aripiprazole appears to reduce cocaine cravings better than the dopamine blocker perphenazine after an acclimation period, according to a small, double-blind randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Otsuka taps Medibio's quantitative mental health assessment for Abilify
Otsuka, the Japanese pharma company that makes the antipsychotic drug Abilify, has partnered with Australian digital health company Medibio to use Medibio ’s system to assess the efficacy of its flagship product. Medibio uses wearable-derived data about heart rate, motion, and sleep to create objective biomarkers for mental illness. (Source: mobihealthnews)
Source: mobihealthnews - October 10, 2017 Category: Information Technology Source Type: news

Abilify vs. Invega
Title: Abilify vs. InvegaCategory: MedicationsCreated: 9/29/2017 12:00:00 AMLast Editorial Review: 9/29/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 29, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS Patient Care - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

FDA Issues Warning About Mixing Opioid Addiction Treatments With Other Meds
TRENTON, N.J. (AP) — The Food and Drug Administration issued new warnings Wednesday about the dangers of combining medication for opioid addiction with anti-anxiety medicines and other drugs that also slow breathing and brain activity. The FDA warned that mixing such drugs can cause difficulty breathing, coma or death, so it should be done with caution. The agency said a growing number of people fighting opioid addiction with methadone or buprenorphine also take other prescription drugs that slow action of the central nervous system. The warning lists several dozen brand-name and generic drugs that could be risky, in...
Source: JEMS: Journal of Emergency Medical Services News - September 20, 2017 Category: Emergency Medicine Authors: Linda A. Johnson, Associated Press Tags: Patient Care News Source Type: news

Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects
Patients show small changes in weight and metabolic parameters from long-term treatment with injectable aripiprazole lauroxil (AL), new research shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Overdoses with aripiprazole: signs, symptoms and outcomes in 239 exposures reported to the Danish Poison Information Center - Christensen AP, Boegevig S, Christensen MB, Petersen KM, Dalhoff KP, Petersen TS.
The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poisons Information Center (DPIC) from June 2007 to May 2015. ... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ReCor Medical adds another $12m for trial of Paradise renal denervation device
ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning. In May 2016 Otsuka participated in a strategic investment of an unspecified amount; Weiss told us that that round and the $12 million debt financing added last week are earmarked for the Radiance-HTN efficacy study of the Paradise device, which is designed to use ultrasoun...
Source: Mass Device - August 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Funding Roundup Wall Street Beat Hypertension ReCor Medical Source Type: news

Injectable, extended-release bipolar drug wins FDA nod
Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News. The post Injectable, extended-release bipolar drug wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Lundbeck Otsuka Pharmaceutical Source Type: news

FDA Approves Long-acting Injectable for Bipolar Disorder FDA Approves Long-acting Injectable for Bipolar Disorder
The FDA has approved extended-release injectable aripiprazole for maintenance monotherapy for bipolar disorder in adults.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena ® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 28, 2017 Category: Drugs & Pharmacology Source Type: news

Addition of Aripiprazole Ups Major Depressive Disorder Remission
Small increased likelihood of remission at 12 weeks in patients with major depressive disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - July 12, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Psychiatry, Journal, Source Type: news

For Treatment-Resistant Depression, Add an Antipsychotic or Switch Antidepressants? (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM For patients with depression unresponsive to antidepressants, adding the antipsychotic aripiprazole seems modestly better than switching to the antidepressant bupropion, a JAMA study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 12, 2017 Category: Primary Care Source Type: news

Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant
(The JAMA Network Journals) Among patients unresponsive to an antidepressant medication, adding the antipsychotic aripiprazole modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by JAMA. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 11, 2017 Category: International Medicine & Public Health Source Type: news

Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis
For children and adolescents with first-episode psychosis, the second generation antipsychotics quetiapine extended release and aripiprazole have equivalent efficacy, but different side effect profiles, according to a head-to-head comparison.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

FDA Approves Longer-Acting Aripiprazole for Schizophrenia FDA Approves Longer-Acting Aripiprazole for Schizophrenia
The FDA has approved a 2-month dose of aripiprazole lauroxil extended-release injectable suspension for the treatment of schizophrenia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 6, 2017 Category: Drugs & Pharmacology Source Type: news

Otsuka, Proteus resubmit FDA application for novel drug-device combination
One year after the FDA declined to approve Proteus Digital Health and Otsuka's new sensor-embedded formulation of Otsuka's antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. (Source: mobihealthnews)
Source: mobihealthnews - May 23, 2017 Category: Information Technology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 23, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Philips picks up airway clearance device dev RespirTech Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount. St. Paul, Minn.-based RespirTech was founded ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet. The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

aripiprazole (Abilify, Abilify Maintena, Aristrada)
Title: aripiprazole (Abilify, Abilify Maintena, Aristrada)Category: MedicationsCreated: 2/17/2004 12:00:00 AMLast Editorial Review: 5/1/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 1, 2017 Category: Drugs & Pharmacology Source Type: news

Improve Your Mood With Turmeric Root (Curcumin)
"Dr. Sears," C.R. asked me, "I know curcumin is good for treating a lot of things, but can it improve someone's mood?" This morning, one of the women on my staff, C.R., came into my office to talk to me about her 15-year-old son. He'd been irritable and moody and sleeping a lot lately. Most mornings, he'd miss the bus to school and then stress about being late. But today, he was up on time with his backpack packed and a smile on his face. C.R. even heard him whistling in the shower! And he was at the bus stop 10 minutes early. C. R. started taking curcumin supplements a few weeks ago. She ha...
Source: Al Sears, MD Natural Remedies - March 21, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Abilify (Aripiprazole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 21, 2017 Category: Drugs & Pharmacology Source Type: news

We Must Fight Rhino Poaching With Science And Dismiss Superstition
A recent story about poachers breaking into the zoo in Paris and killing a rhino to saw off its horn has led to Czech and Belgian zookeepers pre-emptively sawing off the horns of their rhinos in captivity to thwart potential poachers. That sort of supply-reduction thinking will work just as effectively as fumigating illicit cocaine crops and banning assault weapons. You cannot repeal the law of supply and demand. So long as there is demand for rhino horns, cocaine, and assault weapons, someone will step up to supply them. The demand for cocaine and assault weapons seems easy to understand. But does everybody know why poach...
Source: Science - The Huffington Post - March 16, 2017 Category: Science Source Type: news

Aristada (Aripiprazole Lauroxil Extended-release Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 13, 2017 Category: Drugs & Pharmacology Source Type: news

The drug that makes you binge on sex, gambling and food
The antipsychotic drug Abilify, used to treat schizophrenia and depression, is at the center of hundreds of lawsuits over claims that side effects included gambling and binge shopping (Source: the Mail online | Health)
Source: the Mail online | Health - February 17, 2017 Category: Consumer Health News Source Type: news

Once-Monthly Aripiprazole Effective in Bipolar Disorder Once-Monthly Aripiprazole Effective in Bipolar Disorder
The once-monthly injection, currently available for schizophrenia, is seen as a potentially important tool to prevent nonadherence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Aripiprazole Tablets (Aripiprazole Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2017 Category: Drugs & Pharmacology Source Type: news

Aripiprazole Oral Solution (Aripiprazole Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2017 Category: Drugs & Pharmacology Source Type: news

Odds of early death in Alzheimer's patients nearly doubles after taking antipsychotic drugs
(NaturalNews) Alzheimer’s patients who take antipsychotic drugs have a significantly increased risk of dying early compared to those who don’t, new research out of Finland has found. An in-depth analysis of nearly 58,000 people diagnosed with Alzheimer’s disease between 2005 and 2011 found that those who take popular antipsychotics like Abilify (aripiprazole) or Risperdeal (risperidone)... (Source: NaturalNews.com)
Source: NaturalNews.com - January 4, 2017 Category: Consumer Health News Source Type: news

Florida, other states settle with Bristol-Myers Squibb over antipsychotic drug
Florida will get a piece of a $19.5 million settlement with Bristol-Myers Squibb Co. in a case alleging the drug company improperly marketed Abilify. According to a multi-state complaint filed by Florida Attorney General Pam Bondi and attorneys general in 42 other states and the District of Columbia, Bristol-Myers Squibb (NYSE: BMY) promoted the antipsychotic drug for treating elderly patients and children for uses that were not approved by the U.S. Food& Drug Administration. See the final judgment… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 12, 2016 Category: Biotechnology Authors: Margie Manning Source Type: news

Morning Break: Heroin Deadlier than Guns; Abilify Fines; Interstate Insurance Flops
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - December 9, 2016 Category: Respiratory Medicine Source Type: news

Bristol-Myers Squibb to pay $19.5 million over Abilify marketing
Bristol-Myers Squibb on Thursday struck a $19.5 million settlement to resolve claims by 43 states, that it marketed an antipsychotic drug to elderly patients and children for unapproved conditions. Massachusetts Attorney General Maura Healey said in a statement that more than $400,000 of the funds would go to the state. BMS (NYSE: BMY), which is headquartered in New York City and has a manufacturing facility in Devens, Mass., was accused of engaging in unfair and deceptive trade practices t hrough… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 9, 2016 Category: Biotechnology Authors: Max Stendahl Source Type: news

Effect of aripiprazole augmentation for the depressive symptoms changes with progression of Lewy body disease - Iwamoto K, Fujishiro H, Ozaki N.
This report shows that aripiprazol... (Source: SafetyLit)
Source: SafetyLit - November 25, 2016 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

UCLA awarded grant to study depression in older adults
More than half of older adults who are treated for depression find that eventually their treatments are no longer effective. When depression persists, these people are at greater risk of accelerated aging, declining mental health and even suicide.To help address this, UCLA and four other institutions have been awarded a $13.9 million grant to evaluate treatment strategies for older adults with depression who have not responded to medications. UCLA psychiatry professor Dr. Helen Lavretsky will serve as principal investigator on this new study.“No more than 30 to 40 percent of people respond to first-line treatments,&r...
Source: UCLA Newsroom: Health Sciences - September 30, 2016 Category: Universities & Medical Training Source Type: news